The field of microbiome research would not be where it is today without the aid and expertise provided by essential companies such as CosmosID, BioRankings and Second Genome, all of who were in attendance. These companies specialize in mapping the microbiome, discovery and data analysis that helps to identify microbes and microbial markers that influence human health.
MD Biosciences showcased our presence in the field with data from recent cutting edge research in the area of how the microbiome impacts the progression and treatment of cancer. While the focus of microbiome research has centered primary on diseases of the gut, it has recently switched to other peripheral diseases including cancers of extra-gastrointestinal origin. Our lead scientist Britnie James, Ph.D. presented "Understanding the Impact of Animal Vendors and the Microbiome in Tumor Progression and Treatment in a Model of Metastatic Breast Cancer" which demonstrated the impact of the microbiome on the progression of breast cancer as well as the antitumor immune response following doxorubicin treatment.
To learn more about MD Biosciences current investigations into this area, please contact us below!
Also, check out our previous blog: Impact of Vendor Animal Microbiomes on Disease.